GC Cell Set to Participate in the US Cancer Moonshot Project
Initiative aims to reduce cancer mortality rates by 50% in the next 25 years.
GC Cell announced in a company press release that it will be joining CancerX, part of the US Cancer Moonshot project. Started by the Biden administration, the Cancer Moonshot aims to reduce cancer patient mortality rates by over 50% over the next 25 years. According to the company, it aims to highlight the importance and potential of cell therapy in cancer treatment through participating in the initiative.
"I am pleased to contribute to projects that can change the lives of many patients and their families,” said James Park, CEO, GC Cell.” “The Cancer Moonshot & CancerX provides an expanded opportunity to build diverse collaborative research and partnership frameworks with global companies."
Reference: GC Cell Joins US Cancer Moonshot Project. PR Newswire. October 24, 2023. Accessed October 25, 2023. https://www.prnewswire.com/news-releases/gc-cell-joins-us-cancer-moonshot-project-301966721.html
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
